
FY2020 Fourth Quarter Earnings Presentation: Three & Twelve Months Ended 9.30.2020

ZACH PARKER | PRESIDENT & CEO KATHRYN JOHNBULL | CFO

12.07.20









Forward-looking Statements

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this presentation due to a variety of factors, including: the outbreak of the novel coronavirus ("COVID-19"), including the measures to reduce its spread, and its impact on the economy and demand for our services, which are uncertain, cannot be predicted, and may precipitate or exacerbate other risks and uncertainties; the failure to achieve the anticipated benefits of the IBA acquisition (including anticipated future financial operating performance and results); diversion of management's attention from normal daily operations of the business and the challenges of managing larger and more widespread operations resulting from the acquisition; the inability to retain IBA employees and customers; contract awards in connection with recompetes for present business and/or competition for new business; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid protest, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations of IBA and any future acquisitions; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.



Fiscal 2020 Full Year Highlights

Annual revenue rose 30% to \$209.2 million

Earnings of \$7.1 million, or \$0.54 per share

Operating cash flow of \$19.5 million

Completed acquisition of IBA

Backlog of \$688.4 million

"DLH has, once again, performed very well under rather unpredictable and challenging circumstances, solidifying its leadership position in the federal markets we serve."

- Zach Parker, CEO



Key Awards and Backlog Expansion



Modernized Solutions for Head Start Monitoring and Analytics Drives Major Recompete Win and Efficiencies to Client





Major Extensions and Favorable Progress on Heritage Veterans Pharma Contracts



COVID-19 Related Expansion of Infectious Disease Research and Prevention



Military Health System Contracts, Talent and Capabilities Acquired in Fourth Quarter




Election Impact -- Neutral to Positive

- Election not materially change outlook for DLH core markets, although Biden Administration has articulated interest in increased healthcare initiatives
- VA, DoD, and HHS largely supported by both parties, with high-priority programs designed to address the health and safety of Americans
- Will continue to engage applicable Senate and House Committees as appropriate to remain informed









Veterans Health







Military Applications





Pandemic Response Creates *Opportunities* and minor *Headwinds* for Near-term

Expanding portfolio of mission-critical related services across key government agencies

Research and clinical trials for investigational therapies



- Telehealth technology to expand pathways to care
- Active pipeline for short- and long-term R&D

Federal, state, local government pandemic-related guidelines and restrictions

Closure and limitations of facilities scheduled for inspection




Restrictions on DLH subject matter experts travel





Top Priority Focus and Investments



Health and Safety of our uniquely talented workforce

Guided by our Covid-19 Executive Task Force (screenshot) Telework tools, masks & PPE, facility provisions, surveys Evolution of business practices for the "NextNormal"



Collaborate, Innovate, and Accelerate for Growth

Leverage recent infusion of new Leadership Talent
Expanded innovative solution architect resources (differentiate)
Effective integration with reconstructed growth engine




Deploy secure large-scale data analytics platform

Certified Paas / IaaS solution for Cyber and Health IT markets Major government-wide Health IT IDIQs on the horizon Complements expanded Agile, DevOps, Artificial Intelligence





FY2020 Q4 Results: Revenue



FY20 Q4 reflects deferrals in monitoring and compliance programs and reduction of non-labor costs due to pandemic conditions




FY2020 Q4 Results: Operating Income



Operating Income for FY20 Q4 increased as compared to FY19 Q4 when adjusted for \$0.9 million of acquisition costs



FY2020 Q4 Results: EBITDA




EBITDA for FY20 Q4 in line with FY19 Q4 after factoring in \$0.9 million of acquisition expense



A reconciliation of net income to EBITDA is provided in the back of this presentation.

Strengthening and Broadening our Contract Backlog

Amount in millions



Fiscal 2019 ending balance	\$ 414
Additions	
Head Start recompete win	150
IBA acquisition	141
Balance of net contract addtions	193
Reductions	
Fiscal 2020 revenue incurred	 (209)
Fiscal 2020 ending balance	 688
Fiscal 2020 backlog growth	\$ <u> 274</u>
YoY % Growth	66%



Debt Position and Outlook

	<u>S3</u> <u>Acquisition</u>			<u>IBA</u> Acquisition
(\$ in Thousands)	6/7/19	9/30/19	3/31/20	9/30/20
Debt				
Term debt (legacy)	\$ 70,000	\$ 56,000	\$ 53,000	\$ 37,000
Term debt (IBA)	-	-	-	33,000
Revolving debt			2,000	
Total debt	70,000	56,000	55,000	70,000
Cash on hand	(1,900)	(1,790)	(1,124)	(1,357)
Net debt	\$ 68,100	\$ 54,210	\$ 53,876	\$ 68,643
Total Leverage Ratio	3.47	2.67	2.60	2.80

Continued strong operating cash flow anticipated for fiscal 2021, leading to a projected yearend debt balance of \$50 to \$52 million.

Net Debt is a non-GAAP metric used by investors and lenders and management believes it provides relevant and useful information to investors and other users of our financial data. Net Debt is calculated by subtracting cash and cash equivalents from the sum of current and long-term debt





Appendix

Non-GAAP Reconciliations

This document contains non-GAAP financial information including EBITDA, Adjusted EBITDA, and Adjusted EBITDA as a percentage of revenue. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results, and providing meaningful period-to-period comparisons. These measures should be used in conjunction with, rather than instead of, their comparable GAAP measures. A reconciliation of non-GAAP measures to the comparable GAAP measures is presented in this document. The Company defines Adjusted EBITDA as net income excluding interest expense, provision for or benefit from income taxes, depreciation and amortization, and acquisition costs and defined Adjusted EBITDA as a percent of revenue is Adjusted EBITDA divided by revenue. Definitions of the other non-GAAP measures we use in the presentation are contained in the Company's most recent earnings press release, which is available on the investor relations section of our web site at www.dlhcorp.com.

Debt Covenant

We are also including Total Leverage Ratio in this presentation. Total Leverage Ratio is used for the purpose of testing the Maximum Total Leverage Ratio covenant in our Amended and Restated Credit Agreement dated September 30, 2020 (the "Credit Agreement"), which provides for a maximum total leverage ratio of 3.75 to 1.00 for all periods from closing date to September 30, 2021. Management considers the Total Leverage Ratio to be an important indicator of the Company's ability to incur additional debt, its ability to service existing debt and the extent of our compliance with the leverage covenant in the Credit Agreement. We believe that analysts and investors use this metric to assess the Company's ability to service existing debt and our liquidity, generally. The reconciliation of the Total Leverage Ratio is presented in the appendix to this presentation. As used in this presentation, Total Leverage Ratio, which is not calculated in accordance with GAAP, is defined as total debt as of the respective date(s) presented herein, divided by Consolidated EBITDA for the period(s) then ended. Total Leverage Ratio and Consolidated EBITDA are calculated in accordance with the Credit Agreement.



FY2020 Q4 and Full Year EBITDA Reconciliation

(amounts in thousands)		Thr	Ionths En		Twelve Months Ended								
		September 30,						September 30,					
		2020		2019		Change		2020		2019		Change	
Net income	\$	1,363	\$	1,565	\$	(202)	\$	7,114	\$	5,324	\$	1,790	
(i) Interest expense, net		781		1,190		(409)		3,441		2,473		968	
(ii) Provision for taxes		554		639		(85)		2,906		2,171		735	
(iii) Depreciation and amortization		1,664		1,919		(255)		7,003		3,956		3,047	
EBITDA		4,362		5,313		(951)		20,464		13,924		6,540	
Acquisition costs		930		<u> </u>		930	_	930		1,391		(461)	
Adj. EBITDA		5,292	_	5,313	_	(21)	_	21,394	_	15,315	_	6,079	
Net income as a % of revenue		2.7%		2.9%		(0.2%)		3.4%		3.3%		0.1%	
Adj. EBITDA as a % of revenue		10.4%		9.8%		0.6%		10.2%		9.5%		0.7%	
Revenue	\$	50,691	\$	54,183	\$	(3,492)	\$	209,185	\$	160,391	\$	48,794	



A History of Solid Growth









Trending EBITDA Reconciliation

Twelve Months Ended

September 30,

(amounts in thousands)	2	2013	:	2014	2015	2016	- 2	2017	2018	2019	2020
Net (loss)/income	\$	(159)	\$	5,357	\$ 8,728	\$ 3,384	\$	3,288	\$ 1,836	\$ 5,324	\$ 7,114
(i) Interest expense/other (income)		407		4	(744)	823		1,228	1,116	2,473	3,441
(ii) (Benefit)/provision for taxes		-		(4,597)	(5,488)	(938)		2,114	5,830	2,171	2,906
(iii) Depreciation and amortization		121		106	55	1,244		1,754	2,242	3,956	7,003
EBITDA	\$	369	\$	870	\$ 2,551	\$ 4,513	\$	8,384	\$ 11,024	\$ 13,924	\$ 20,464



Reconciliation of Leverage Ratio

	<u>S3</u> Acquisition			<u>IBA</u> Acquisition
(amount in thousands)	6/7/19	9/30/19	3/31/20	9/30/20
Term Loan	\$ 70,000	\$ 56,000	\$ 53,000	\$ 70,000
Revolving Credit Loan	-	-	2,000	-
Letters of Credit		1,745	1,745	1,990
Total Funded Debt	\$ 70,000	\$ 57,745	\$ 56,745	\$ 71,990
Consolidated EBITDA	\$ 20,162	\$ 21,664	\$ 21,795	\$ 25,678
Total Leverage Ratio	3.47	2.67	2.60	2.80

Consolidated EBITDA as calculated per the Credit Agreement.



